Eli Lilly presented new trial data. Eli Lilly stock gains 1.09 percent

Lilly's October 9, 2026 release compared 482 proteins with 140 by Week 36. Eli Lilly stock costs EUR 1,056.20 on October 12, 2026 versus EUR 1,044.80.

Eli Lilly and Co. (ISIN US5324571083) was trading at EUR 1,056.20 at Lang & Schwarz on October 12, 2026 at 12:10 p.m. CEST, up 1.09 percent versus the Xetra close of October 9, 2026 at EUR 1,044.80. Eli Lilly and Company presented new exploratory TOGETHER-PsO Phase 3b data on October 9, 2026, comparing Taltz and Zepbound with Taltz alone.

Three recent clinical milestones

On September 15, 2026, Lilly outlined cardiometabolic data for the EASD meeting, including 17.00 percent weight loss with Eloralintide added to tirzepatide versus 10.00 percent with tirzepatide alone, according to Eli Lilly and Company. On October 5, 2026, the company said 21 presentations would cover its dermatology portfolio at Fall Clinical 2026, according to Eli Lilly and Company. The October 9 release then reported 482 versus 140 differentially expressed proteins and 467 versus 16 genes by Week 36 in the combination and monotherapy arms.

What does the data add?

The study enrolled 274 participants and tested the combination in adults with psoriasis and obesity or overweight. The numerical spread in biomarker responses is the clearest new signal: the combination affected more than three times as many proteins as Taltz alone by Week 36, while the gene count was more than 29 times higher.

The findings remain exploratory rather than a new regulatory approval. Lilly said the earlier Week 36 primary-endpoint results showed superior skin clearance and meaningful weight reduction for the combination, with improvements maintained or further improved through Week 52. The release also listed safety as consistent with the known profile of each medicine.

Revenue supports the valuation

In the second quarter of 2026, Eli Lilly reported USD 23.0 billion of revenue, up 47.70 percent from the second quarter of 2025, and USD 7.10 billion of net income, according to StockFactsheet. The same period produced a gross margin of 85.80 percent. That growth gives the clinical pipeline a financial backdrop, but the stock also reflects demanding expectations, with a USD 1.1 trillion market capitalization as of October 9, 2026.

On October 9, 2026, BofA lowered its price target to USD 1,341 from USD 1,344 while keeping a Buy rating, according to Markets Insider. The target change is modest, but it highlights the balance between rapid revenue expansion and the execution risk attached to new products and clinical milestones.

Next earnings date is October 29

Eli Lilly and Company lists its third-quarter 2026 earnings call for October 29, 2026 at 10:00 a.m. EDT. That report will show whether the 47.70 percent second-quarter revenue growth is continuing into the second half of the year.

Stock gains against the Xetra close

Eli Lilly stock was trading at EUR 1,056.20 at Lang & Schwarz on October 12, 2026 at 12:10 p.m. CEST, up 1.09 percent versus the Xetra close of October 9, 2026 at EUR 1,044.80. The NYSE-listed stock had a USD 783.85 to USD 1,292.65 52-week range as of October 9, 2026.

The further course of trading is shown by the continuously updated real-time quote of Eli Lilly stock.

Eli Lilly stock facts

• Company: Eli Lilly and Company
• ISIN: US5324571083
• Ticker: LLY
• Primary exchange: NYSE
• Price Lang & Schwarz (as of October 12, 2026, 12:10 p.m. CEST): EUR 1,056.20
• Change versus Xetra close: plus 1.09 percent
• Xetra close (October 9, 2026): EUR 1,044.80
• Market capitalization: USD 1.1 trillion (as of October 9, 2026)
• 52-week range: USD 783.85-1,292.65 (as of October 9, 2026)
• Sector / Industry: Health care / Pharmaceuticals
• Next earnings date: October 29, 2026

Market context: Market report S&P 500.

More news and analyses on Eli Lilly stock